A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Filgotinib (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms MANTA
- Sponsors Gilead Sciences
- 12 Feb 2018 Planned End Date changed from 1 Sep 2022 to 1 Oct 2024.
- 12 Feb 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Jan 2021.
- 15 Aug 2017 Planned number of patients changed from 200 to 250.